Thus, our findings of positive association between CD8+ T cells and CD4+ T cells, as well as other immune cells, and LOX family members suggest that ICB and other immunotherapy could have a promising potential in LC treatment as high expression of LOX family members in tumor tissues facilitates immune cells infiltration, which could induce the immune response exerting the antitumor efficiency. The gene discussed is CD8A; the disease is laryngotracheoesophageal cleft.